Besides vaccines, mRNA technology is being explored for therapeutic applications in oncology, infectious diseases, genetic disorders, and other areas. This diversification expands the market potential. The mRNA vaccines and therapeutics market was projected to attain...
Huntingtin. Crystallographic structure of the N-terminal region of the human Huntingtin protein with an artificially attached Maltose-Binding protein used for crystallographic purposes. Credit: Public domain In Huntington’s disease, the mutant huntingtin gene...
On July 8th, Moderna, Inc. and Mitsubishi Tanabe Pharma Corporation (MTPC) officially entered into a joint agreement to co-promote Moderna’s mRNA respiratory vaccine portfolio in Japan, alongside Moderna’s COVID-19 vaccine, Spikevax. Moderna’s Success Sparks...
GSK on Wednesday announced it is restructuring an existing collaboration agreement with German biotech CureVac, focusing on their investigational mRNA vaccines for influenza and COVID-19 while withdrawing from other infectious disease projects. Under the amended...
Overview This review article discusses the therapeutic potential of gene editing, focusing on mRNA-based delivery systems. It highlights the advancements in gene editing technologies like CRISPR-Cas systems and base editors, and examines their applications in treating...
